| Literature DB >> 33403490 |
Emel Sokullu1,2, Reza Rahbarghazi3,4, Hesam Saghaei Bagheri5, Mohammad Karimipour5, Morteza Heidarzadeh6, Hadi Rajabi5.
Abstract
The COVID-19 pandemic has profoundly influenced public health and contributed to global economic divergences of unprecedented dimensions. Due to the high prevalence and mortality rates, it is then expected that the consequence and public health challenges will last for long periods. The rapid global spread of COVID-19 and lack of enough data regarding the virus pathogenicity multiplies the complexity and forced governments to react quickly against this pandemic. Stem cells represent a small fraction of cells located in different tissues. These cells play a critical role in the regeneration and restoration of injured sites. Because of their specific niche and a limited number of stem cells, the key question is whether there are different anti-viral mechanisms against viral infection notably COVID-19. Here, we aimed to highlight the intrinsic antiviral resistance in different stem cells against viral infection. These data could help us to understand the possible viral infections in different stem cells and the activation of specific molecular mechanisms upon viral entrance.Entities:
Keywords: Anti-viral defense system; COVID-19; Mature cells; Stem cells
Mesh:
Year: 2021 PMID: 33403490 PMCID: PMC7785129 DOI: 10.1007/s12015-020-10108-4
Source DB: PubMed Journal: Stem Cell Rev Rep ISSN: 2629-3277 Impact factor: 5.739
Fig. 1SARS-CoV-2 is encased within a fatty membrane (envelop) and has a very large genomic pool with nucleotides around 3 × 104. The viral structure is composed of membrane protein, nucleoprotein, envelope small membrane protein, hemagglutinin, single-strand positive sensel RNA, and spike glycoprotein (a). Two types of cup-shaped spike glycoproteins subunits S1 and S2 are present on the viral surface which attach the viral body to the host cellular receptor ACE-2 (b). Membrane protein = M; Nucleoprotein = N; Envelope small membrane protein = E; and Hemagglutinin = HE. The illustration was created with BioRender.com
Fig. 2The proliferation of SARS-CoV-2 within the host cells initiates soon after attachment of S protein (S1 and S2) to the cell membrane-bound ACE-2 receptor. Allosteric changes in S protein promote viral envelope fusion with the cell membrane through endosomal signaling. Inside the cells, the genomic pool is released, transcribed, and translated to synthesize various components of viral structure. Finally, viral proteins and genome RNA are assembled into virions in the endoplasmic reticulum and Golgi apparatuses and transported into microvacuoles. In the next, step, the microvesicles containing virions are released. After infection of host cells with COVID-19 nanoparticles, the release of virions promotes pyroptosis and massive cellular damage. The neighboring cells such as endothelial cells, dust cells (alveolar macrophages) start to release an array of cytokines and chemokines. With the progression of cellular damage, blood lymphocytes (either T and B), as well as macrophages, are recruited to the site of infection. Accumulation of immune cells exacerbates the inflammatory responses by the continuous production of inflammatory cytokines. Interleukine 10: IL-10; Interleukine 6: IL-6; granulocyte colony-stimulating factor: G-CSF; Macrophage inflammatory protein 1α: MIP1α; Interferon-gamma: IFNγ; Interleukine 2: IL-2; Tumour necrosis factor-α: TNF-α. The illustration was created with BioRender.com
Fig. 3different intracellular mechanisms used by stem cells to inhibit the proliferation and expansion inside these cells. The illustration was created with BioRender.com
List of antiviral mechanisms in different stem cell types
| Stem Cell type | Effector | Mechanism of action | Ref |
|---|---|---|---|
| Mouse ESCs, PSCs, hiPSCs, TSCs, MSCs, NSCs, and PnSCs | RNA interference (RNAi) pathway | Viral RNA synthesis ↓ | [ |
| Mouse ESCs, iPSCs, PSCs | Dicer-1 and Dicer-2 | miRNA biogenesis and siRNA biogenesis↑ | [ |
| Human iPSCs, TSCs, mouse ESCs, iPSCs, | Argonaute (Ago) | Formation of RNA-induced silencing complex (RISC) ↑ | [ |
| Somatic stem cells, ESCs, TSCs, Skeletal stem cells, iPSCs, MSCs, NSCs, and PnSCs | Component 3 Promoter of RISC | Activation of RISC ↑, Argonaute2 (Ago2)-associated RNAi↑ | [ |
| iPSCs, MSCs, NSCs, and PnSCs | Ars2 and heat shock proteins | siRNA biogenesis↑, RNA-protein complexes ↑, Conformational changes during RISC loading↑ | [ |
| SoSCs | piRNA | Antiviral defense↑ | [ |
| ESCs | RNase-III enzyme Dicer-2 | Recognition of cytoplasmic dsRNA↑ | [ |
| ESCs and respiratory epithelial cells | miRNA | miRNA-induced silencing complex (miRISC) attachment to target sites in the 3’ untranslated regions (UTR) of mRNAs↑, translational repression↑, de-adenylation↑, and mRNA decay↑ | [ |
| NSCs | interferon-α/β receptor (IFNAR) | JAK-STAT pathway↑, ISGs↑ | [ |
| Primary stem cells, NSC, Human ESCs | Interferon stimulated genes (ISGs) | Viral replication↓ Adaptive immune response↑, transcription of Mx1, and RIM5↓, translation of PKR, IFIT family members, OASL↓, RNA degradation and apoptosis (RNase L)↑ | [ |
| NSCs, MSCs, mouse ESCs | Type I IFNs | Chemokine release↑, Antigen presentation by innate immune cells↑, antibody production↑, and T cell responses↑ | [ |
| NSCs, MSCs, mouse ESCs | TLR3, RIG-I, and MDA5 | Recognition of viral dsRNA↑, IRF3↑, IRF7↑, and NF-kB ↑, IFN ↑ | [ |
| HSCs, ESCs, iPSCs, germ layer cells | ISG12 | Cell death ↑, Cytochrome C release↑, Caspase activation↑ | [ |
| Mouse ESCs, HSCs, ESCs, iPSCs | OAS1 | Innate immune response to viral infection↑, RNase L activity ↑, Viral RNA degradation↑ | [ |
| iPSCs, ESCs, MSCs, NSCs derived from iPSCs | DNA sensors absent in melanoma 2 (AIM2) | Activation of the NLRP3 inflammasome↑, production of IL-1β↑, | [ |
| ESCs, iPSCs | Protein kinase R (PKR) | Virus translation↓, Protein phosphorylation↓, Innate immune responses↑ | [ |
| Human ESCs, HLCs, multipotent germ layer cells, human hiPSCs, TSCs, HSCs, NSCs, MSCs | IFITM1, IFITM3, EIF3L, and BST2 | Replication of viruses↓ Cytosolic entry↓ | [ |
| Human ESCs, HLCs, multipotent germ layer cells, human iPSCs, TSCs, HSCs, NSCs, MSCs | IFN Response and IFN pathway | Phosphorylation and nuclear import of IRF-3↑, Post-transcriptional processing of cellular antiviral pre-mRNAs↓ dsRNA binding properties↓, RNA processing↓, trafficking ↓, translational ↓ | [ |
| Bone marrow MSCs, HSCs, ESCs, iPSCs | Mitochondrial antiviral-signaling protein (MAVS) | Activation of NF-kB, IRF3 and IRF7 and ISGs↑ | [ |
| HSCs, ESCs, iPSCs, germ layer cells. | IFIT family | Recognition of 5ʹ triphosphate ↑, Viral protein translation↓ | [ |
| Mouse ESCs, and human ESCs | Ribonuclease L (RNase L) | Single-stranded RNA degradation in U-rich sequences↑, Antiviral innate Immunity↑ | [ |
| Human ESCs, HLCs, Multipotent germ layer cells, human iPSCs, TSCs, HSCs, NSCs, MSCs | Interferon regulatory factor 3 (IRF3) | Glial cytokine expression↑, pro-inflammatory cytokines ↓, Anti-inflammatory or immunoregulatory cytokines↑ | [ |
| Glioma stem cells | Interferon Regulatory Factor (IRF-7) | Antiviral responses ↑ and NF-κB expression↓ | [ |
| CySCs, Germline stem cells | JAK/STAT pathway | Upregulation of ISGs↑ | [ |
| HSCs, ESCs, iPSCs, germ layer cells. | Interferon-inducible transmembrane proteins (IFITMs) | Cytosolic entry↓ | [ |
| ESCs, HSC, multipotent adult stem cells, BMSCs, Skeletal stem cells, SoSCs | Bone marrow stromal antigen 2 (BST-2) | Inoculation site viral load↓, Viremia ↓, and lymphoid tissues tropism↑ | [ |
| Human ESCs, human hiPSCs, mouse ESCs | Suppressor of cytokine signaling 1 (SOCS1) | IFN signaling↓, phosphorylation of type I IFN receptor ↓ JAK kinase activity↓ phosphorylation of STAT1↓ | [ |
| NSCs, MSCs, ESCs | IFN-β | Virus entry↓, Transcription↓, Translation↓, Genome Replication↓, Assembly↓, and egress ↓ | [ |
| NSCs, MSCs, mouse ESCs | IFN-λ1 and -λ2 | Replication of virus ↓, Cytotoxic activity ↓, CC chemokine expression ↑, Viral entrance ↓ | [ |
| ESCs, iPSCs, NSCs | NF-κB | NF-κB-LTRs attachment↑, Replication early during the viral life cycle↑ | [ |
| Human ESCs, HLCs, multipotent germ layer cells, human iPSCs, TSCs, HSCs, NSCs, MSCs | RNA helicase MOV10 | Retro-transposition and Interferon-stimulated genes ↓, Repression of ERVs beyond antiviral proteins↑ | [ |
| HSCs, CD34+ stem cells, ESCs, iPSCs | small interfering RNAs (siRNAs) | Sequence-specific defense against viruses and transposons, Bind to Argonaut protein↑ | [ |
Bone marrow stromal cells: BMSCs; Hematopoietic stem cells; Hepatocyte-like cells: HLCs; Induced pluripotent stem cells: iPSCs; Mesenchymal stem cells; MSCs; Neural Stem Cells; NSCs; Pancreatic stem cells: PnSCs; Somatic cyst stem cells: CySCs; Somatic stem cells: SoSCs; Tissue stem cells: TSCs
Fig. 4Cross-talk between TLRs and NrF2 signaling pathways in the viral infection. Endosomal TLRs including TLR 3,4,7,8,9 recognize the viral ssRNA and dsRNA. Stimulation of TLR7 by viral RNAs causes the production of NADPH oxidase which is an imperative factor in the connection of two signaling pathways and in results activation of NrF2 downstream pathways. Additionally, activation of TLR3 leads to the production of other anti-oxidant elements related to NrF2 pathways such as HO-1, which participates in the activation process of stress response transcription factors including NrF2, NF-KB, and AP-1. TLR 3 and 7 also appreciate the initiation of autophagy which can deliver the nucleic acid fragments of viruses to the endosomal TLRs and leads them to degradation by recruiting autolysosomes. On the other hand, NrF2 signaling pathways are in a relationship with the stemness of stem cells by inhibiting the activation of OCT4 and NANOG proteins by using ubiquitin/proteasome. The illustration was created with BioRender.com
Fig. 5The similarity in exosome biogenesis and virus assembly system makes virus to use exosome biogenesis pathways for delivery and cell exit. The illustration was created with BioRender.com